false
0001471727
0001471727
2026-04-17
2026-04-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): April 17, 2026
SRx
Health Solutions, Inc.
(Exact
name of Registrant as Specified in its Charter)
| Delaware |
|
001-40477 |
|
83-4284557 |
(State
or other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
801
US Highway 1
North
Palm Beach, Florida 33408
(Address
of Principal Executive Offices) (Zip Code)
(Registrant’s
Telephone Number, Including Area Code): (212) 896-1254
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, $0.001 par value share |
|
SRXH |
|
NYSE
American |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01. Regulation FD Disclosure
On
April 17, 2026, the SRx Health Solutions, Inc. (the “Company”) issued a press release updating its stockholders regarding
the progress on its previously announced transaction with EMJ Crypto Technologies Inc. (“EMJC”) A copy of the press
release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.
The
information in Item 7.01 of this Current Report shall not be deemed to be “filed” for the purposes of Section 18 of the Securities
and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section,
nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act, except as shall be expressly set forth by specific reference in such a filing.
Forward-Looking
Statements
This
current report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Exchange Act, which are intended to be covered by the “safe harbor” created by those sections. All statements
in this current report that are not based on historical fact are “forward looking statements.” These statements may be identified
by words such as “estimates,” “anticipates,” “projects,” “plans,” “strategy,”
“goal,” or “planned,” “seeks,” “may,” “might”, “will,” “expects,”
“intends,” “believes,” “should,” and similar expressions, or the negative versions thereof, and which
also may be identified by their context. All statements that address operating performance or events or developments the Company expects
or anticipates will occur in the future, such as stated objectives or goals, refinement of strategy, attempts to secure additional financing,
exploring possible business alternatives, or that are not otherwise historical facts, are forward-looking statements. While management
has based any forward-looking statements included in this current report on its current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements as a result of various factors, including risks associated with the Company’s
ability to obtain additional capital in the future, the proposed transaction with EMJC, general economic factors, competition in the
industry and other factors that could cause actual results to be materially different from those described herein as anticipated, believed,
estimated or expected. Additional risks and uncertainties are described in or implied by the Risk Factors and Management’s Discussion
and Analysis of Financial Condition and Results of Operations sections of the Company’s 2025 Annual Report on Form 10-K, filed
on February 13, 2026 and other reports filed from time to time with the Securities and Exchange Commission (“SEC”).
The Company urges you to consider those risks and uncertainties in evaluating its forward-looking statements. Readers are cautioned to
not place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required
by the federal securities laws, the Company disclaims any obligation or undertaking to publicly release any updates or revisions to any
forward-looking statement contained herein (or elsewhere) to reflect any change in its expectations with regard thereto, or any change
in events, conditions, or circumstances on which any such statement is based.
Item
9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibits |
|
Description |
| 99.1 |
|
Press Release, dated April 17, 2026. |
| 104 |
|
Cover
Page Interactive Data File (Embedded within the Inline XBRL document) |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
SRx
Health Solutions, Inc. |
| |
|
|
| |
By: |
/s/
Carolina Martinez |
| |
Name: |
Carolina
Martinez |
| |
Title: |
Chief
Financial Officer |
April
17, 2026
Exhibit
99.1

SRx
Health Solutions and EMJX Issue Letter to Shareholders from Eric M. Jackson
EMJ
Crypto Technologies (EMJX) Founder and CEO Mr. Jackson provides update on operational progress and timing of proposed merger between
SRx Health Solutions and EMJX
NORTH
PALM BEACH, FL — April 17, 2026 — SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”) and EMJ
Crypto Technologies (“EMJX”), a digital-asset treasury operating platform with which the Company has entered into a definitive
merger agreement, today released a letter to shareholders providing an update on the proposed transaction from Eric. M. Jackson, the
creator of the EMJX platform. Mr. Jackson will be appointed as an officer of the Company’s EMJC subsidiary following the merger.
Dear
Shareholders,
I
wanted to take this opportunity to provide an update on our latest progress and the merger agreement between the Company and EMJX. As
most of you are aware, the Company entered into a definitive agreement to acquire EMJX, the next-generation (“Gen2”) digital-asset
treasury platform I founded.
I
have spent over 20 years in public markets, most recently running EMJ Capital, with a PhD in Management from Columbia Business School.
I can sincerely say I am excited about the opportunity we have with this transaction to drive value for shareholders.
Operational
Progress in 2026
Since
announcing this merger in December 2025, we’ve made substantial operational progress. First, we deployed $18 million into our second-generation
digital asset treasury hedging strategy, delivering a 5.69% return in March 2026 compared to a 4.98% decline in the S&P 500 index
amid ongoing global uncertainty. This amounts to a 10.67% outperformance over the S&P 500 during this period. Through mid-April,
we achieved approximate gains of 3.5% and 8% in our hedging pool and long treasury investment holdings, respectively. Second, we’ve
been engaging in business development and market education discussions across the U.S. investment community and businesses, showcasing
the institutional capabilities of our platform.
These
past few months have laid the groundwork for EMJX’s future. We’ve proven out our operating system, which applies quantitative
models, artificial intelligence, and systematic risk controls to multi-asset digital treasury management. We believe this Gen2 framework
reflects the continued maturation of digital-asset treasuries toward more disciplined, institutional-grade capital management models.
What
we have brought to market is structurally different to what we have typically seen in history: Gen1 treasury approaches that rely on
price appreciation of a single asset and typically lack systematic risk management, exposing shareholders to significant drawdowns and
dilution during adverse market conditions. In contrast, our Gen2 approach is structured as a platform that governs how capital is allocated,
hedged, and reinvested across market cycles, rather than functioning as a passive balance sheet tracking asset values. This distinction
is important because for EMJX, we have spent a lot of time focusing on governance and rules to build a system based on intelligence.
In essence, EMJX is a treasury operating system - not a fund, nor crypto fund, nor a hedge fund, but something built to last.

As
we look forward, we have been focused on expanded treasury deployment to areas we believe have high growth potential. Just yesterday,
the Company announced it had acquired shares in the open market of Compass Inc. and increased its investment in Opendoor Technologies
Inc.
Update
on Timing
I
understand that complex corporate transactions like this can create uncertainty, but I want to reiterate my confidence in this deal and
its ability to propel our business and deliver long-term shareholder value.
This
week, the Company filed a registration statement on Form S-4 with the SEC for this important transaction. SRXH’s Board of
Directors and EMJX are committed to maximizing shareholder value through this transaction and structuring the post-merged company in
a way that best aligns with all shareholders. Now that the S-4 is filed, we will undergo a regulatory review period – a typical
process for this type of transaction – and, pending approval, we will then be cleared to close. We are following the clear process
as laid out by the SEC, but hope to conclude this as soon as possible.
Upon
completion, the EMJX platform will operate through a wholly-owned subsidiary of the Company. As Founder of EMJX, I am proud of the performance
that it is delivering so far and I am thrilled to show what we can do in the future.
To
close, I want to thank you, as shareholders, for your continued support and patience. We look forward to providing further updates in
the future.
Regards,
Eric.
M. Jackson
EMJX
Founder & Chief Executive Officer
Additional
Information and Where to Find It
In
connection with the proposed transaction between the Company has filed with the SEC a Registration Statement on Form S-4 (the “Registration
Statement”) to register the common stock to be issued in connection with the proposed transaction. The Registration Statement includes
an information statement of the Company and a prospectus of the Company (the “Information Statement/Prospectus”), and each
of EMJX and the Company may file with the SEC other relevant documents concerning the proposed transaction. After the Registration Statement
is declared effective, the definitive Information Statement/Prospectus will be sent to the stockholders This is not a substitute for
the Registration Statement, the Information Statement/Prospectus or any other relevant documents that EMJX or the Company has filed or
will file with the SEC. BEFORE MAKING ANY INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO CAREFULLY AND ENTIRELY
READ THE REGISTRATION STATEMENT AND INFORMATION STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS,
AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION
ABOUT EMJX, THE COMPANY, THE PROPOSED TRANSACTION, AND RELATED MATTERS. A copy of the Registration Statement, Information Statement/Prospectus,
as well as other relevant documents filed by EMJX and the Company with the SEC, may be obtained free of charge, when they become available,
at the SEC’s website at www.sec.gov. The information on EMJX’s or the Company’s respective websites is not, and shall
not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.

No
Offer or Solicitation
This
communication is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation
of an offer to buy or sell any securities or the solicitation of any proxy, vote or approval, nor shall there be any sale of securities
in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities
laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section
10 of the Securities Act, or in a transaction exempt from the registration requirements of the Securities Act.
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such
as “believe,” “expect,” “intend,” “aim,” “plan,” “may,” “could,”
“target,” and similar expressions are intended to identify forward-looking statements. These statements are based on current
expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those
expressed or implied. These risks include, but are not limited to, the ability to complete the proposed transaction, shareholder approvals,
market conditions, regulatory considerations, and other risks described in the Company’s filings with the Securities and Exchange
Commission. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them, except
as required by law.
Company
Contact
SRx
Health Solutions, Inc.
Kent
Cunningham, Chief Executive Officer
Investor
Relations Contact
KCSA
Strategic Communications
Valter
Pinto, Managing Director
212-896-1254
valter@kcsa.com